Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 84

Sort by

Sort Order Select

Journal Articles

A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice

Blood (2021) 138 (14): 1258–1268.

https://doi.org/10.1182/blood.2020010331

Published: 2021

Includes: Supplemental data

Journal Articles

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

Blood (2021) 137 (16): 2231–2242.

https://doi.org/10.1182/blood.2020009217

Published: 2021

Includes: Supplemental data

Journal Articles

How much clotting is enough?

Laurent O. Mosnier

Blood (2020) 136 (6): 651–652.

https://doi.org/10.1182/blood.2020006443

Published: 2020

Journal Articles

A hemophilia A mouse model for the in vivo assessment of emicizumab function

Stephen Ferrière, Ivan Peyron, Olivier D. Christophe, Charlotte Kawecki, Caterina Casari, Vincent Muczynski, Amit Nathwani, Alexandre Kauskot, Peter J. Lenting, Cécile V. Denis

Blood (2020) 136 (6): 740–748.

https://doi.org/10.1182/blood.2019004334

Published: 2020

Includes: Supplemental data

Journal Articles

A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors

Guy Young, Ri Liesner, Tiffany Chang, Robert Sidonio, Jr, Johannes Oldenburg, Victor Jiménez-Yuste, Johnny Mahlangu, Rebecca Kruse-Jarres, Michael Wang, Marianne Uguen, Michelle Y. Doral, Lilyan Y. Wright, Christophe Schmitt, Gallia G. Levy, Midori Shima, Maria Elisa Mancuso

Blood (2019) 134 (24): 2127–2138.

https://doi.org/10.1182/blood.2019001869

Published: 2019

Includes: Supplemental data

Journal Articles

Peri-Procedural Management and Outcomes of Patients with Hemophilia on Emicizumab Prophylaxis

Isabella McCary, BS, Christine Guelcher, PPCNP-BC, Jan Kuhn, BA, BSN, MSN, Regina Butler, RN-BC, Michael F. Guerrera, MD, Gita Massey, Leslie J. Raffini, MD

Blood (2019) 134 (Supplement_1): 2396.

https://doi.org/10.1182/blood-2019-126944

Published: 2019

Journal Articles

Prospective Controlled Monitoring of Hemlibra Prophylaxis Initiation in a Large Cohort of Hemophilia a Patients- Real World Data

Assaf Arie Barg, Tami Livnat, PhD, Tami Brutman-Barazani, Nurit Rosenberg, Ivan Budnik, MD PhD, Gili Kenet

Blood (2019) 134 (Supplement_1): 2397.

https://doi.org/10.1182/blood-2019-122010

Published: 2019

Journal Articles

Factor VIII Use in the Treatment of Breakthrough Bleeds in Hemophilia A Patients without Inhibitors on Emicizumab Prophylaxis: The Phase 3 HAVEN 3 Study Experience

Michael Callaghan, MD, Benjamin Trzaskoma, MS, Richard H. Ko, MD, Lucy Lee, PharmD, Anisha M. Patel, PhD, Eunice Tzeng, PharmD, Michelle Lynn Shah, PharmD, Tiffany Y. Chang, MD MAS, Markus Niggli, PhD, Christophe Dhalluin, PhD, Johnny Mahlangu, MMed, FCPath

Blood (2019) 134 (Supplement_1): 2395.

https://doi.org/10.1182/blood-2019-123654

Published: 2019

Journal Articles

Emicizumab-Kxwh for Previously Untreated Patients with Haemophilia: The Conversation Begins

Tiffany Lin Lucas, MD, Shveta Gupta, MBBS, Joanna A. Davis, MD, Fernando F. Corrales-Medina, MD

Blood (2019) 134 (Supplement_1): 2409.

https://doi.org/10.1182/blood-2019-127270

Published: 2019

Journal Articles

Cost-Effectiveness Model of Recombinant FVIII Versus Emicizumab Treatment of Patients With Severe Hemophilia A Without Inhibitors

Shawn X. Sun, Yanyu Wu, Michael McDermott, Marjolijn van Keep

Blood (2019) 134 (Supplement_1): 2102.

https://doi.org/10.1182/blood-2019-124421

Published: 2019

Journal Articles

In Vivo hemostatic Significance of Activated Protein C in Factor VIIIa Regulation

Amelia R. Wilhelm, B.S., Nicole A. Parsons, B.S., Charles T. Esmon, PhD, Rodney M. Camire, PhD, Lindsey A. George, MD

Blood (2019) 134 (Supplement_1): 93.

https://doi.org/10.1182/blood-2019-124493

Published: 2019

Journal Articles

Mim8 - a Next-Generation FVIII Mimetic Bi-Specific Antibody - Potently Restores the Hemostatic Capacity in Hemophilia a Settings in Vitro and In Vivo

Blood (2019) 134 (Supplement_1): 96.

https://doi.org/10.1182/blood-2019-122817

Published: 2019

Journal Articles

Emicizumab Prophylaxis in Patients with Hemophilia Α with and without Inhibitors

Patrick T. Ebbert, BS, Frederico Xavier, MD MS, Craig D. Seaman, MD MS, Margaret V. Ragni, MD MPH

Blood (2019) 134 (Supplement_1): 2416.

https://doi.org/10.1182/blood-2019-123198

Published: 2019

Journal Articles

Evaluation of a Next-Generation FVIII Mimetic Antibody, Mim8, in Combination with Recombinant FVIIa, FVIII and Activated Prothrombin Complex Concentrate

Laurent Burnier, PhD, Mette B Hermit, PhD, Ida Hilden, Mirella Ezban, PhD, Stine L Kjellev, PhDDVM

Blood (2019) 134 (Supplement_1): 2388.

https://doi.org/10.1182/blood-2019-123340

Published: 2019

Journal Articles

Beliefs, Opinions, and Impact of Emicizumab on Hemophilia Patients: A National U.S. Survey

Hanny Al-Samkari, MD, Stacy E. Croteau

Blood (2019) 134 (Supplement_1): 3395.

https://doi.org/10.1182/blood-2019-125364

Published: 2019

Journal Articles

Central Line-Associated Thrombus Formation in an Inhibitor Negative Severe Hemophilia A Patient on Emicizumab

Nicholas B George, MD, Alexander Paschke, Katie Scott, MD

Blood (2019) 134 (Supplement_1): 4938.

https://doi.org/10.1182/blood-2019-127105

Published: 2019

Journal Articles

Characterization and Disease Management of Persons with Hemophilia A Treated with Emicizumab: A Survey Study of Hematologists in the US

Wendy E. Owens, MA, Anisha M. Patel, PhD, Kathleen Poulos, RN, Janet Bernard, BA, Janet Powers, MPH, MBA, Richard H. Ko, MD

Blood (2019) 134 (Supplement_1): 4941.

https://doi.org/10.1182/blood-2019-123730

Published: 2019

Journal Articles

Characteristics of Hemophilia A Patients Treated with Emicizumab: an Early View using Claims Database Analysis

Arash Mahajerin, MD MS, Erru Yang, MS, Anisha M. Patel, PhD

Blood (2019) 134 (Supplement_1): 4928.

https://doi.org/10.1182/blood-2019-123724

Published: 2019

Journal Articles

Comparison of Bypassing Agents in Patients on Emicizumab Using Global Hemostasis Assays

Hande Kizilocak, Elizabeth Marquez-Casas, BS, Jemily Malvar, MS, Roxana Carmona, MD, Guy Young, MD

Blood (2019) 134 (Supplement_1): 904.

https://doi.org/10.1182/blood-2019-132050

Published: 2019

Journal Articles

Bone and Joint Health Markers in Persons with Hemophilia A (PwHA) Treated with Emicizumab in HAVEN 3

Anna Kiialainen, PhD, Markus Niggli, PhD, Christine L. Kempton, MD MSc, Giancarlo Castaman, MD, Tiffany Y. Chang, MD MAS, Ido Paz-Priel, MD, Joanne I Adamkewicz, PhD, Gallia G. Levy, MD PhD

Blood (2019) 134 (Supplement_1): 626.

https://doi.org/10.1182/blood-2019-123689

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

How much clotting is enough?

A hemophilia A mouse model for the in vivo assessment of emicizumab function

A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors

Peri-Procedural Management and Outcomes of Patients with Hemophilia on Emicizumab Prophylaxis

Prospective Controlled Monitoring of Hemlibra Prophylaxis Initiation in a Large Cohort of Hemophilia a Patients- Real World Data

Factor VIII Use in the Treatment of Breakthrough Bleeds in Hemophilia A Patients without Inhibitors on Emicizumab Prophylaxis: The Phase 3 HAVEN 3 Study Experience

Emicizumab-Kxwh for Previously Untreated Patients with Haemophilia: The Conversation Begins

Cost-Effectiveness Model of Recombinant FVIII Versus Emicizumab Treatment of Patients With Severe Hemophilia A Without Inhibitors

In Vivo hemostatic Significance of Activated Protein C in Factor VIIIa Regulation

Mim8 - a Next-Generation FVIII Mimetic Bi-Specific Antibody - Potently Restores the Hemostatic Capacity in Hemophilia a Settings in Vitro and In Vivo

Emicizumab Prophylaxis in Patients with Hemophilia Α with and without Inhibitors

Evaluation of a Next-Generation FVIII Mimetic Antibody, Mim8, in Combination with Recombinant FVIIa, FVIII and Activated Prothrombin Complex Concentrate

Beliefs, Opinions, and Impact of Emicizumab on Hemophilia Patients: A National U.S. Survey

Central Line-Associated Thrombus Formation in an Inhibitor Negative Severe Hemophilia A Patient on Emicizumab

Characterization and Disease Management of Persons with Hemophilia A Treated with Emicizumab: A Survey Study of Hematologists in the US

Characteristics of Hemophilia A Patients Treated with Emicizumab: an Early View using Claims Database Analysis

Comparison of Bypassing Agents in Patients on Emicizumab Using Global Hemostasis Assays

Bone and Joint Health Markers in Persons with Hemophilia A (PwHA) Treated with Emicizumab in HAVEN 3

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only